About
Connect to Cure™
Synaffix is a biotech company with a clinical-stage platform technology that enables best-in-class antibody-drug conjugates (ADCs), bispecific antibodies and other targeted therapeutics under a technology out-licensing business model. Synaffix was fully acquired by Lonza in June 2023.
Aimed at enabling innovative medicines for patients in areas of high unmet medical need, Synaffix has forged a growing number of collaborations with top tier biotech and pharma companies by enabling best-in-class therapeutic candidates for their pipelines.
Company Timeline
Deal Expansion with Innovent (1801:HK)
New deal builds on encouraging preliminary clinical data from the Phase 1 study of the first antibody-drug conjugate (ADC) developed under the agreement signed in June 2021
Deal with SOTIO
Synaffix signs out-licensing deal with SOTIO worth up to $740m
Synaffix Launch 2 New ADC Technologies at the World ADC San Diego
New technologies will further enhance the ability of our licensees to discover, develop and commercialize ADCs with best-in-class therapeutic properties
Deal with ABL Bio (KOSDAQ: 298380)
Licensing Agreement with ABL Bio for up to three programs
Lonza announces acquisition of Synaffix
As a Lonza company, Synaffix will continue to operate under the Synaffix name and further expand its operations in Oss (NL) to cater for further innovation and growth
Expansion of MacroGenics Collaboration
Expanded collaboration worth up to $2.2 billion
Chong Kun Dang Pharm Licenses Synaffix ADC Technology
First Synaffix partnership announced with a Korean company
Deal with Hummingbird Bioscience
Synaffix signs out-licensing deal worth up to $150m
Winner ‘Business Development Team of Year’ Award
Synaffix Received ‘Business Development Team of Year’ at the Scrip Awards
Winner ‘Biotech Company of the Year’ Award
Synaffix Named ‘Biotech Company of the Year’ at the LSX European Lifestars Awards
Synaffix obtains exclusive rights to the CliCr® technology from Cristal Therapeutics
Synaffix Licenses CliCr® Chemistry from Cristal Therapeutics to Fortify Best-in-Class ADC Technology Offering
Winner ‘Best ADC Platform Technology’ Award
Synaffix Wins ‘Best ADC Platform Technology’ Award Again at World ADC Awards Ceremony 2022
Deal with Emergence Therapeutics
Synaffix signs out-licensing deal with Emergence worth up to $360M
Deal Expansion with Kyowa Kirin
License agreement with Kyowa Kirin based on latest positive ADC data
Deal with Macrogenics (NASDAQ:MGNX)
Synaffix signs out-licensing deal with Macrogenics worth up to $586m
Deal with Genmab (NASDAQ:GMAB)
Synaffix signs exclusive out-licensing deal with Genmab worth up to $415m
Deal with Mersana (NASDAQ:MRSN) Expanded
Synaffix expands the 2019 deal with Mersana to over $1 billion.
Deal with Kyowa Kirin (TYO:4151)
Kyowa Kirin Taps Synaffix ADC Technology to Expand Its Pipeline
Deal with ProfoundBio
Synaffix signs out-licensing deal with ProfoundBio worth up to $246m
Deal with Innovent (1801:HK)
Synaffix signs out-licensing deal with Innovent, providing access to GlycoConnect™, HydraSpace® and toxSYN® platforms for ADC development and commercialization
Winner "Best ADC Platform Technology" Award
Synaffix awarded “Best ADC Platform Technology” at World ADC Awards ceremony
Deal with Miracogen
Synaffix signs out-licensing deal with Miracogen worth up to $125m
Deal with Mersana (NASDAQ:MRSN)
Synaffix signs out-licensing deal with Mersana worth up to $295m
toxSYN® Linker-Payloads Launched
Synaffix launches toxSYN® linker-payloads as extension of its existing platform, enabling any company with an antibody to develop proprietary, best-in-class ADCs
Deal with ADC Therapeutics (NYSE:ADCT)
Synaffix signs initial out-licensing deal with ADC Therapeutics, providing access to GlycoConnect™ and HydraSpace® for ADC development and commercialization
High Potency Lab Opens
High potency lab comes online, facilitating safe handling of highly-potent ADCs and ADC payloads
SAB Established
Leading industry experts appointed to Scientific Advisory Board (SAB)
Series A Financing
Series A financing, backed by top-tier investor syndicate including Aravis, BioGeneration Ventures, BOM Capital and M Ventures
